Drugs / Lerapolturev
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03043391 | Nov 2017 → Mar 2022 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, atypical teratoid rhabdoid tumor +4 | Istari Oncology, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04690699 | Aug 2021 → Apr 2024 | non-invasive bladder urothelial carcinoma | Istari Oncology, Inc. | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06177964 | Jul 2024 → Feb 2029 expected | glioblastoma | Darell Bigner | Recruiting | No outcome recorded |
| Phase 2 | NCT04577807 | Nov 2020 → Nov 2024 | melanoma | Istari Oncology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04479241 | Oct 2020 → Jun 2024 | brain neoplasm, glioblastoma | Istari Oncology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02986178 | Jun 2017 → Sep 2022 | malignant glioma | Istari Oncology, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lerapolturev | “Viral immunotherapy, such as the polio-rhinovirus chimera lerapolturev, is a novel approach for treatment of recurrent paediatric high-grade glioma” PMID 37004712 ↗ Mar 2023 |
| Known as | PVSRIPO | “LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients...” NCT04690699 ↗2“Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma” NCT04479241 ↗ “Lerapolturev (PVSRIPO) in GBM” NCT06177964 ↗ |
| Modality | Other / unclassified | “an oncolytic polio/rhinovirus recombinant” NCT02986178 ↗ |
| Route | Other | “Patients will be administered lerapolturev intratumorally via convection-enhanced delivery (CED)” NCT02986178 ↗ |